Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literature
Benedikt Schoser(Evangelisches Krankenhaus Bielefeld), Peter Young(University of Münster), Derralynn Hughes(Royal Free London NHS Foundation Trust), Edward Fong(Stanford University), Harm A.W.M. Tiddens(Radboud University Nijmegen), David Orlikowski(Hôpital Raymond-Poincaré), Mark Roberts(Sherwood Forest Hospitals NHS Foundation Trust), John T. Kissel(The Ohio State University Wexner Medical Center), Tarekegn Geberhiwot(Selly Oak Hospital), Shyam Madathil(Queen Elizabeth Hospital Birmingham), Michael I. Polkey(The Task Force for Global Health)
Cited by 109
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522
An official European Respiratory Society statement on physical activity in COPD
|European Respiratory Journal|2014|519
The prevalence of quadriceps weakness in COPD and the relationship with disease severity
|European Respiratory Journal|2009|486
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
|Journal of the American Society of Nephrology|2016|421